ERBB2 and neoplasm: Evaluation of HER2 status should align with the current ASCO/CAP guidelines, encompassing the IHC score ranging from 0 to 3 + , intensity and pattern of staining, and the percentage of positive cells with the highest staining pattern seen in > 10% of invasive tumor cells.